CONCLUSIONS
In re-operative AVR via upper partial re-sternotomy after CABG with
patent bypass grafts, MIrAVR may prevent fatal complications, such as
graft injury, by minimizing tissue detachment. Although further
development of the TAVI technology is expected to change treatment
methods in the future, MIrAVR after CABG is currently a viable treatment
option.